E2F-1 controls multiple cellular activities through transcriptional regulation of its target genes. As a mediator of cell death, E2F-1 can eliminate latent neoplastic cells through apoptosis. However, the mechanism by which E2F-1 mediates cancer cell killing is largely unknown. In this paper, we report that phosphatase of activated cells 1 (PAC1) phosphatase is a direct transcription target of E2F-1 in signaling apoptosis. We show that ectopic E2F-1 increases expression of PAC1 at both transcriptional and translational levels in breast cancer cells. E2F-1 physically interacts with the promoter of PAC1, binds to its consensus sequence in the promoter and transactivates the PAC1 promoter. E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxyphenylretinamide (4-HPR). Furthermore, ectopic PAC1 inhibits ERK phosphorylation and mediates cell killing. Moreover, endogenous E2F-1 upregulates PAC1 and suppresses ERK activity, leading to cell death in response to 4-HPR. These results reveal a crucial role of PAC1 in E2F-1-directed apoptosis. Our study demonstrates that E2F-1 mediates apoptosis through transcriptional regulation of PAC1 and subsequent suppression of the ERK signaling. Our findings establish a functional link between E2F-1 and mitogen-activated protein kinases. The E2F-1-PAC1 cascade in cancer cell killing may provide a molecular basis for cancer therapeutic intervention.
Introduction
The E2F-1 transcription factor plays a central role in cell cycle control and apoptosis (DeGregori et al., 1997; Bell and Ryan, 2004) . E2F-1 has two opposite properties: the oncogenic form of E2F-1 can promote cell cycle progression (Zhu et al., 1994; Cam and Dynlacht, 2003) , whereas its induction of apoptosis reflects its tumor suppressive property (Field et al., 1996; Ginsberg, 2002) . E2F-1 knockout mice develop a broad spectrum of tumors (Yamasaki et al., 1996) and E2F-1-deficient mice exhibit defects in apoptosis (Field et al., 1996) , suggesting that E2F-1 is a tumor suppressor and that it is necessary for apoptotic cell death in certain tissues. However, the role of E2F-1 in chemotherapeutics and its mechanism of action are largely unknown. The induction of cancer cell killing is a major strategy in cancer therapeutics. Identification of E2F-1 target genes involved in apoptosis may shed light on the mechanism whereby E2F-1 functions in tumor treatment. A paucity of transcription targets of E2F-1 have been found to mediate apoptosis, the most significant one being the tumor suppressor p73 Lissy et al., 2000) . Another apoptosis-related target gene of E2F-1 is apoptosis protease-activating factor 1 (Furukawa et al., 2002) . Various cellular stimuli can generate oxidative stress, which is implicated in the activation of transcription factors and the initiation of protective responses for elimination of damaged cells by apoptosis (Huang et al., 1996; Mates and Sanchez-Jimenez, 2000) . Therefore, identification of new E2F-1 downstream genes, particularly those involved in apoptotic responses to oxidative stress and chemotherapeutic drugs, would illustrate how E2F-1 inhibits tumor growth under cellular stress conditions and how chemotherapeutical treatment coordinates with E2F-1 in suppression of tumor progression.
PAC1 (phosphatase of activated cells 1; also known as DUSP2) is an inducible, nuclear-specific and dual threonine/tyrosine phosphatase that can specifically inactivate mitogen-activated protein (MAP) kinases (Rohan et al., 1993; Ward et al., 1994) . MAP kinases compose a key intracellular signaling pathway that transduces signals of extracellular stimuli to the nucleus (Lewis et al., 1998; Whitmarsh and Davis, 1999 ). There are three major classes of MAP kinases: the extracellular signal-regulated kinase (ERK), c-Jun Nterminal kinase (JNK) and p38 (Lewis et al., 1998; Miyata and Nishida, 1999) . The activity of MAP kinases is regulated by a series of phosphorylation-dependent switches. MAP kinases are activated upon dual phosphorylation by MAP kinase kinase and inactivated upon dephosphorylation of tyrosine and threonine residues by MAP kinase phosphatases (Sun et al., 1993; Chu et al., 1996) . PAC1 has a highly selective, dual-specificity phosphatase activity toward ERK more than p38 or JNK (Zhang et al., 2005) . Therefore, it is important to determine the role of PAC1 in apoptosis and its potential in cancer therapeutics.
Our previous study has characterized PAC1 as an essential mediator of apoptosis in the p53 pathway and as a critical molecular link between p53 and the MAP kinase pathway (Yin et al., 2003) . In this study, we provide evidence to place PAC1 in the E2F-1 apoptotic pathway, and furthermore, reveal its potential efficacy in sensitizing cancer cells to oxidation-related chemotherapeutic treatment. We first identify PAC1 as a direct transcriptional target of E2F-1 in signaling E2F-1-mediated apoptotic cell death. The E2F-1-dependent induction of PAC1 leads to inhibition of ERK1/2 activity and increased apoptotic sensitivity to a chemotherapeutic drug, fenretinide (N-4-hydroxyphenylretinamide, 4-HPR), a synthetic retinoid effective that can increase reactive oxygen species (ROS) generation (Malone et al., 2003) . The new E2F-1/PAC1 pathway provides an intracellular signaling platform through which anticancer drugs may suppress cell survival signaling and promote apoptosis. The fact that PAC1 can induce apoptosis following 4-HPR treatment in an E2F-1-dependent manner highlights the potential role of PAC1 in cancer chemotherapeutics.
Results
Transcriptional regulation of PAC1 by E2F-1 Our main aim was to evaluate the potential role of E2F-1 in mediating apoptosis of breast cancer cells. In order to search for new targets of E2F-1 in signaling breast cancer cell killing, we chose MB435, a breast cancer cell line, to create a working model. The E2F-1 expression plasmid was introduced into these MB435 cells and two clones, MB435/E2F1-C2 and MB435/E2F1-C3, were selected for analysis of ectopic E2F-1 levels, compared with control cells, MB435/pcDNA3. As shown in Figure 1a , there are high levels of E2F-1 transcripts in these two stable clones expressing ectopic E2F-1 (lane 1 vs lanes 2 and 3). Consistently, the levels of E2F-1 protein are high in these cell lines (Figure 1b ). Using this model, we performed microarray analysis of gene profiles to identify E2F-1-inducible genes in breast cancer cells. We found that PAC1 is highly induced in the cells expressing ectopic E2F-1. We have previous demonstrated that PAC1 is a transcription target of p53 in apoptosis (Yin et al., 2003) . Because p53 and E2F-1 coordinate to induce cell death, it is possible that E2F-1 also regulates the expression of PAC1 in signaling apoptosis. To validate our microarray data, we took conventional approaches to detect expression of PAC1 in these cells. As shown in Figure 1c , whereas PAC1 transcripts are low in control MB435/pcDNA3 cells, its transcription level is increased in both E2F-1 overexpressing clones, particularly in MB435/E2F1-C3 cells. Figure 1 Induction of PAC1 by E2F-1 at both transcriptional and translational levels. (a) Human MB435 breast cancer cells were transfected with an E2F-1 expression plasmid pcDNA3/E2F1. The abundance of E2F-1 was detected by northern blotting. GAPDH was used as a loading control. (b) Ectopic expression of E2F-1 protein was detected by western analysis using an E2F-1-specific monoclonal antibody (UBI). Equal amounts of protein were shown by reprobing the same blot with an anti-b-actin antibody (Santa Cruz). (c) Induction of PAC1 in human MB435 cells expressing ectopic E2F-1. mRNA was isolated from indicated MB435 cells with or without ectopic E2F-1 for detection of PAC1 by northern blotting. (d) Increased expression of PAC1 in response to E2F-1 overexpression. Cell lysates from indicated cells were prepared for western analysis of PAC1 expression by using a monoclonal anti-PAC1 antibody (Santa Cruz). b-Actin level was shown as a loading control. GAPDH, glyceraldehydes-3-phosphate dehydrogenase; PAC1, phosphatase of activated cells 1.
E2F-1/PAC1 cascade in cell killing by chemotherapeutics J Wu et al Consistently, the levels of PAC1 protein are increased in these cells with ectopic E2F-1 (Figure 1d ). These results suggest that E2F-1 regulates PAC1 expression at the transcriptional level. However, the patterns of cell cycle distribution of MB435/pcDNA3 and MB435/E2F-1 are similar (Supplementary Figure 1) , suggesting that ectopic expression of E2F-1 does not induce cell cycle changes in MB435 cells, which contain mutant p53.
Transactivation of the promoter of human PAC1 gene Our results reveal a relationship between E2F-1 and PAC1 in breast cancer cells. The next question was how E2F-1 regulates PAC1 expression. It is well established that E2F-1 regulates its target genes through binding to its consensus sites in the promoters involved. Indeed, our subsequent analysis of the PAC1 promoter sequence revealed a consensus E2F-1 binding motif near the transcription start site (data not shown). We constructed a luciferase reporter driven by the PAC1 promoter containing the E2F-1-binding site and conducted the luciferase assay to test whether E2F-1 can induce PAC1 promoter activity. Compared with the empty vector, cotransfection of the E2F-1 expression plasmid with the PAC1 luciferase reporter yielded an over 15-fold induction of the PAC1 promoter activity (Figure 2a) . Interestingly, deletion of the E2F-1 binding site from the PAC1 reporter leads to a complete abrogation of luciferase activity. Point mutation of the E2F-1 consensus site also eliminates transactivity of the luciferase reporter by E2F-1 (Figure 2a ). These results suggest that E2F-1 binding to its consensus site on the PAC1 promoter is essential for transactivation of the promoter. These data demonstrate that PAC1 is a transcription target of E2F-1.
Physical interaction between E2F-1 and the PAC1 promoter To determine whether E2F-1 is physically associated with the PAC1 promoter in vivo, we conducted a chromatin immunoprecipitation (ChIP) assay in MB435 cells, with or without ectopic E2F-1, using the anti-E2F1 monoclonal antibody. Amplification of the PAC1 promoter from genomic DNA as input results in positive PCR products, regardless of the presence of ectopic E2F-1 (Figure 2b, lanes 1-3) . However, this promoter is almost absent in chromatin-immunoprecipitated products from the MB435/pcDNA3 control cells (Figure 2b , lane 4), whereas the ChIP samples from MB435/E2F1 cell clones yield clear promoter bands (Figure 2b , lanes 5 and 6). As control, ChIP by an anticyclic AMP-responsive element-binding protein (anti-CREB) antibody did not produce the specific PCR fragments corresponding to the PAC1 promoter. These results demonstrate that E2F-1 is associated with the human PAC1 promoter in vivo.
Because the region containing the E2F-1 consensus sequence is essential for activation of the PAC1 promoter, it is possible that E2F-1 binds to this site. To test this possibility, we performed an electrophoretic mobility shift assay (EMSA) to determine whether E2F-1 protein binds to its consensus sequence from the PAC1 promoter. A 34-bp oligonucleotide including the E2F-1 binding site was synthesized and labeled with [g-32 P]ATP as a probe. Incubation of this probe with purified recombinant glutathione-S-transferase (GST)-E2F-1 fusion protein yielded a clear band shift ( Figure 3 , lane 2). The E2F-1-associated 34W-PAC1 is eliminated by addition of excess unlabeled 34W-PAC1 (lane 3), but not by adding a nonspecific 30-bp oligonucleotide (NS30W, lane 4), indicating the binding specificity. To confirm the specific binding of E2F-1 to the 34-bp PAC1 promoter element, an anti-E2F-1 monoclonal antibody Figure 2 Interaction between E2F-1 and the PAC1 promoter (a) Transactivation of the PAC1 promoter by E2F-1. MB435 cells were transiently transfected with a PAC1 promoter luciferase reporter, pGL3-PAC1-1.2-luc, together with an E2F-1 expression plasmid, pcDNA3/E2F1, or an empty vector, pcDNA3. Also, the PAC1 promoter reporter with a point mutation in the E2F-1 consensus site, pGL3-PAC1-1.2 mt-luc, and a shorter form of the PAC1 promoter with a deletion of the E2F-1 consensus binding site, pGL3-PAC1-0.5-luc, were included. The luciferase activity was analysed using a Dual-Light Luciferase Assay kit (Tropix) and luciferase values were normalized against b-galactosidase activity. A summary of three independent experiments (means7s.e.) is shown in the histogram. **Po0.01. (b) ChIP analysis of the physical association between E2F-1 and the PAC1 promoter in vivo. Crosslinked protein-chromatin complexes were immunoprecipitated by an E2F-1-specific monoclonal antibody (UBI), and the E2F-1-associated PAC1 promoter sequence was amplified by PCR using the corresponding primers. The PAC1 promoter amplified directly from genomic DNA from the same panel of cells was used as a positive control. An antibody (anti-CREB) was used as a control for ChIP. ChIP, chromatin immunoprecipitation; CREB, cyclic AMP-responsive element-binding protein; PAC1, phosphatase of activated cells 1; s.e., standard error of the mean.
was included in the reaction. As shown in Figure 3 , addition of the E2F-1 antibody results in a clear supershift band (lane 5), which is eliminated by cold 34W-PAC1 competitor (lane 6). These data indicate that E2F-1 physically binds to its consensus site in the PAC1 promoter. The physical interaction of E2F-1 with the promoter of PAC1 both in vitro and in vivo provides a molecular basis for the activation of the PAC1 promoter ( Figure 2a ) and induction of PAC1 expression by E2F-1 (Figure 1c and d) . The regulatory connection established between the E2F-1 transcription factor and PAC1 phosphatase may offer a molecular mechanism whereby E2F-1 suppresses the MAP kinase survival pathway and causes the biological consequence of cell death.
Suppression of MAP kinases and induction of apoptosis in breast cancer cells by E2F-1 in response to chemotherapeutic treatment As a potent inhibitor of ERK1/2, PAC1 can dephosphorylate MAP kinases ERK1/2. Since E2F-1 upregulates expression of PAC1, E2F-1 may suppress the activity of ERK1/2 through PAC1. Indeed, overexpression of E2F-1 reduces the phosphorylation status of ERK1/2 (Figure 4a, lane 1 vs lanes 2 and 3) . We have previously demonstrated that PAC1 is highly inducible by oxidative damage and that PAC1 causes apoptosis (Yin et al., 2003) . Thus, we investigated the possibility that E2F-1 suppresses ERK1/2 phosphorylation and Figure 3 Physical binding of E2F-1 to the PAC1 promoter in vitro. Purified GST-E2F-1 fusion protein or GST control was incubated with [g-32 P]ATP-labeled PAC1 oligonucleotide containing the E2F-1 consensus sequence (34W) for an EMSA. The E2F1 monoclonal antibody (Santa Cruz) was included in reactions for supershift. A 50-fold excess of unlabeled wild-type PAC1 corresponding oligonucleotide (cold 34W) and a labeled random oligonucleotide (NS30W) were used for the competition and specificity controls, respectively. EMSA, electrophoretic mobility shift assay; GST, glutathione-S-transferase; PAC1, phosphatase of activated cell. E2F-1/PAC1 cascade in cell killing by chemotherapeutics J Wu et al mediates cell death following chemotherapeutic treatment with anticancer drugs, especially those with the potential to kill cancer cells by provoking oxidative stress signaling. 4-HPR is such an agent with promising clinical significance (Malone et al., 2003; Kim et al., 2006) . 4-HPR has been examined extensively in in vitro assays, animal models and clinical trials as a cancer chemopreventive agent. It has been shown that 4-HPR induce cancer cell apoptosis by increasing ROS generation (Kim et al., 2006) . The production of nitric oxide induced by nitric oxide synthase has also been proposed as a mechanism by which 4-HPR suppresses cancer cell growth and induces apoptosis (Simeone et al., 2002 (Simeone et al., , 2003 . 4-HPR can act as a potent inhibitor of mammary carcinogenesis (Moon and Mehta, 1989) to suppress tumor growth and inhibit telomerase activity in animal models (Bednarek et al., 1999) . All of these studies point to the promising clinical significance of 4-HPR. Therefore, we chose to study whether and how the E2F-1-PAC1 signaling cascade mediates cancer cell response to 4-HPR. First, we determined whether 4-HPR acts in an E2F-1-dependent manner to inhibit the MAP kinase survival pathway. Indeed, upon treatment with 4-HPR, a dramatic reduction of ERK1/2 phosphorylation was observed in two cell clones expressing ectopic E2F-1, compared with control cells (Figure 4a , lane 4 vs lanes 5 and 6). As a consequence of the inactivation of the cell survival pathway, cell viability is largely reduced in MB435/E2F-1 cells in comparison with control cells (Figure 4b) , to an extent consistent with the reduction of ERK phosphorylation shown in Figure 4a . These results suggest that 4-HPR inhibits ERK1/2 activation and induces stress-responsive cell death in an E2F-1-dependent manner. To confirm the apoptotic nature of the 4-HPR-induced cell death, we performed a TdT-mediated dUTP nick end labeling (TUNEL) assay to detect the endonucleolytic cleavage of chromatin. Consistent with the results revealed by trypan blue exclusion, only a very small proportion (B7%) of MB435/pcDNA3 control cells are apoptotic by TUNEL assay (Figure 4c , upper panel), indicating a resistance of these cells to 4-HPR-induced apoptosis. In the presence of ectopic E2F-1, however, a significantly larger number of apoptotic cells (>30%) was observed ( Figure 4c , lower panel). These data once again illustrate that E2F-1 sensitizes cancer cells to chemotherapeutic treatment, most likely through the induction of PAC1, a specific antagonist of ERK1/2.
Inhibition of ERK1/2 phosphorylation and mediation of therapeutic response of breast cancer cells by PAC1 As a downstream target of E2F-1, PAC1 may elicit a similar cellular response to anticancer agents. To test this idea, we introduced a PAC1 expression plasmid into MB435 breast cancer cells and generated stable cells expressing ectopic PAC1, designated as MB435/PAC1 (Yin et al., 2003) . The levels of PAC1 expression in MB435/pcDNA3 and MB435/PAC1 clones (C6, C12) were evaluated by western analysis using an anti-PAC1 antibody ( Figure 5a ). As expected, the levels of ERK1/2 phosphorylation are decreased in MB435/PAC1-C6 and MB435/PAC1-C12 (Figure 5b , lane 1 vs lanes 2 and 3). Interestingly, ERK1/2 phosphorylation is further reduced upon treatment with 4-HPR (Figure 5b , lane 4 vs lanes 5 and 6), suggesting that PAC1 can mediate the cellular response to 4-HPR that presumably generates oxidative stress. Consistently, the MB435 cells expressing ectopic PAC1 showed much greater sensitivity to treatment with 4-HPR compared with control MB435/pcDNA3 cells (Figure 5c ). Further examination of the cell death response to 4-HPR revealed a time-dependent curve (Figure 5d ), indicating that the sensitivity of MB435/PAC1 cells to 4-HPR-induced cell death is further increased with longer treatment. These data suggest that as a downstream target of E2F-1, PAC1 acts in the E2F-1 apoptotic pathway to elicit cancer cell killing through suppressing the MAP kinase survival pathway, even in the absence of E2F-1.
Critical role of PAC1 in E2F-1-mediated induction of cancer cell killing Our data in Figure 5 demonstrate the potency of PAC1 in mediating chemotherapeutic drug-induced apoptosis, pointing to its potential clinical value. To further assess how this potency of PAC1 contributes to the E2F-1 apoptotic function upon drug treatment, we introduced small interfering RNAs (siRNAs) of PAC1 into MB435/ E2F1-C3 cells to eliminate the induction of PAC1 by E2F-1. As shown in Figure 6a , The PAC1 siRNA efficiently abrogates E2F-1-induced PAC1 expression in MB435/E2F1-C3 (lane 2 vs lanes 3-5). As a consequence of this PAC1 unresponsiveness, E2F-1 is no longer able to suppress the MAP kinase signaling pathway (data not shown). More importantly, E2F-1 can no longer efficiently mediate the 4-HPR-induced cell death in the absence of PAC1 (Figure 6b ). The effect of PAC1 knockdown on cell killing by E2F-1 was further evaluated by a time-course analysis of cell viability in these cells (Figure 6c ). These data suggest that PAC1 is a critical mediator of E2F-1 function in suppressing the MAP kinase survival pathway. In order to extend our observations, we chose Saos-2, a tumor cell line derived from a sarcoma null for p53 and Rb (Ookawa et al., 1997) . First, we found that PAC1 is induced under 4-HPR in these cells (Figure 7a , lanes 1 and 2). To determine whether this induction of PAC1 is dependent of E2F-1, we introduced an E2F-1 siRNA vector (Shen et al., 2004) into these cells and obtained Saos-2/siE2F-1 cells. We then detected the levels of PAC1 protein in control Saos-2/U6 and in Saos-2/siE2F-1 cells. As shown in Figure 7a , there is no increase of PAC1 expression in Saos-2/siE2F-1 cells, compared with control Saos-2/U6 cells when treated with 4-HPR (lanes 3 and 4), suggesting that E2F-1 is necessary for the induction of PAC1 following 4-HPR treatment of Saos-2 cells. As expected, PAC1 is efficiently knocked down by siPAC1 expression (Figure 7a , lanes 5 and 6). Next, we measured the activity of ERK1/2 in these cells. As expected, the phosphorylation level of ERK1/2 is not decreased in Saos-2/siE2F-1 cells as well as Saos-2/siPAC1 cells, although ERK1/2 is dephosphorylated in control Saos-2/U6 cells following treatment with 4-HPR (Figure 7b ). Our results suggest that endogenous E2F-1 can inhibit the activity of MAP kinases and it does so mainly through PAC1. In order to precisely evaluate the role of the E2F-1/PAC1 pathway in mediating cancer cell killing, we monitored the kinetics of cell death progression following treatment with various concentrations of 4-HPR. As shown in Figure 7c , the viability of Saos-2 cells declines with increasing doses of 4-HPR. In contrast, those cells with reduced levels of either endogenous E2F-1 or PAC1 are relatively resistant to cell killing by 4-HPR. Furthermore, both Saos-2/siE2F-1 cells and Saos-2/siPAC1 form more colonies than Saos-2/U6 control in the presence of 4-HPR (Supplementary Figure 5) . These results demonstrate that E2F-1 and PAC1 are important for induction of cell death in response to chemotherapeutic treatment. Interestingly, other known targets for E2F-1 function in apoptosis are not inducible by 4-HPR in Saos-2 cells (Supplementary Figure 2) , suggesting that E2F-1/PAC1 pathway is a specific cascade for apoptotic signaling.
Discussion
In this paper, we demonstrate that E2F-1 is a transcriptional regulator of PAC1, a dual specificity protein phosphatase that dephosphorylates and inhibits MAP kinases. We report that E2F-1 and PAC1 constitute a cascade essential for chemotherapeutics.
The elimination of cancer cells is the ultimate goal of cancer therapy and one of the challenges in cancer chemotherapeutics is to identify the targets of therapeutic action. Oxidative stress often elicits an apoptotic response (Clarke et al., 1993; Trinei et al., 2002; Yan and Chen, 2006) , which may serve as a mechanism for cancer cell susceptibility to chemotherapeutic drugs (Conklin, 2004) . Therefore, identification of important components involved in the cellular response to oxidative stress may reveal targets for chemotherapeutic strategies. We have previously demonstrated that p53 is essential for the cellular apoptotic response to oxidative stress (Yin et al., 1998 (Yin et al., , 1999 . We further identified two MAP kinase inhibitors, PAC1 and MKP-2, as downstream targets of p53 function in apoptosis signaling (Yin et al., 2003; Shen et al., 2006) . However, because p53 is mutated frequently in human cancer and mutant p53 is dominant over wild-type p53, it is not practical to E2F-1/PAC1 cascade in cell killing by chemotherapeutics J Wu et al restore p53 function by reintroduction of the p53 gene itself into cancer cells in cancer therapy. Therefore, identification of downstream effectors of p53 function that are controlled by other mechanisms intact in cancer cells would be a better approach for chemotherapeutics. Since PAC1 is regulated by both p53 and E2F-1, PAC1 is a dual target in two fundamental pathways and a merger site for cell death signaling. By regulating PAC1 and inhibiting ERK MAP kinases, E2F-1 may serve as a substitute for p53 in apoptotic function and eliminate cancer cells by suppressing ERK kinases following chemotherapy. Interestingly, 4-HPR does not cause cell death in normal human fibroblasts ( Supplementary  Figure 3a and b) . Consistently, PAC1 is not induced and ERK1/2 is not suppressed by 4-HPR in these normal cells (Supplementary Figures 3c and d) . Furthermore, as shown in Supplementary Figure 4 , E2F-1 does not induce cell killing when MB435 are Figure 7 Essential role of the E2F-1-PAC1 signaling cascade in mediating ERK inactivation and cell killing by 4-HPR. (a) Saos-2 osteosarcoma cells were transiently transfected with pSilencer U6/ NS (control), U6/siE2F-1 or U6/siPAC1 plasmids. The expression levels of E2F-1 and PAC1 were detected by western blotting in the indicated cells, with or without the treatment of 4-HPR (10 mM, 4 h). Equal protein loading was shown by reprobing the blot with the b-actin antibody. (b) Phosphorylation of ERK1/2 and total ERK1/2 were examined by western analysis in the same cells described in (a). (c) Cell viability was analyzed by trypan blue exclusion in Saos-2/siE2F1 and Saos-2/siPAC1 cells, as well as control Saos-2/U6 cells treated with different doses of 4-HPR for 24 h. Data presented in the graph were the means7s.e. from three independent experiments of duplicate cultures. Statistical significance compared with control Saos-2/U6 cells: Po0.01 at various doses (10, 12 and 14 mM). ERK, extracellular signal-regulated kinase; 4-HPR, N-4-hydroxyphenylretinamide; PAC1, phosphatase of activated cells 1; s.e., standard error of the mean. The same group of cells as in (a) was subjected to treatment with 4-HPR (10 mM, 24 h). Cell viability was determined by trypan blue exclusion. The data presented in the graph were the means7s.e. from three independent experiments of duplicate cultures (**Po0.01). (c) Cell viability was determined by trypan blue exclusion in the indicated cells treated with 4-HPR (10 mM) for various period of time. The data presented in the curves were the means7s.e. from three independent experiments of duplicate cultures. The cell viability of MB435/E2F1-C3/siPAC1 clones was significantly different from MB435/E2F1-C3/U6 cells (Po0.01), but not significantly different from MB435/pcDNA3 cells. 4-HPR, N-4-hydroxyphenylretinamide; s.e., standard error of the mean; siRNA, small interfering RNA.
E2F-1/PAC1 cascade in cell killing by chemotherapeutics J Wu et al treated with common chemotherapeutic agents such as etoposide, 5-fluorouracil or doxorubicin. However, E2F-1 increases the sensitivity of MB435 cells to indomethacin, which is a nonsteroidal anti-inflammatory drug (NSAID) that induces cancer cell death (Husain et al., 2001) . Therefore, the PAC1/ERK cascade represents a critical target in mediating selective cancer cell killing by some anticancer drugs. E2F-1 transactivates the PAC1 promoter through a physical interaction between E2F-1 and the PAC1 promoter in vitro and in vivo. Therefore, E2F-1 is a direct transcriptional regulator of PAC1. Because PAC1 phosphatase is an inhibitor of the MAP kinase cascade, the identification of PAC1 as a direct target of E2F-1 reveals a functional link between E2F-1 and MAP kinases. Thus, E2F-1 may eliminate cancer cells not through activation of the caspase and mitochondrial pathway used by most of the known cell death mediators (Creagh et al., 2003) , but through suppression of a predominant cell proliferation pathway involving in MAP kinases.
PAC1 is known to be an early response gene that is highly inducible by oxidative stress and causes cell death by apoptosis (Rohan et al., 1993; Yin et al., 2003) . Interestingly, this oxidative stress-responsive signaling pathway can also apply to the response of the same cells to the anticancer therapeutic agent, 4-HPR. 4-HPR is a synthetic retinoid derivative (Malone et al., 2003) that is believed to induce apoptosis by stimulating ROS generation (Kim et al., 2006) . We show that 4-HPR treatment induces expression of PAC1 and reduces ERK1/2 phosphorylation, leading to apoptotic cell death. These data suggest that 4-HPR acts as an inducer of the apoptotic response through the activation of E2F-1/PAC1. Therefore, manipulation of the E2F-1 apoptotic pathway represents an attractive target for cancer therapy. Recruited into the E2F-1 apoptotic pathway, PAC1 is then enabled as an apoptotic mediator. Ectopic expression of PAC1 dephosphorylates ERK1/2 and enhances the sensitivity of MB435 cells to 4-HPR treatment, leading to apoptosis. These results demonstrate that PAC1 can act independently of E2F-1 to sensitize cancer cells to 4-HPR-induced apoptotic cell death. The importance of PAC1 in apoptosis has been further demonstrated by its indispensable role in E2F-1-regulated cancer cell susceptibility to anticancer druginduced apoptosis. When E2F-1-induced PAC1 is abrogated by PAC1 siRNA, loss of this important MAP kinase antagonist invalidates the suppression of MAP kinase activity by E2F-1 and inhibits the cell death process induced by 4-HPR.
Taken together, the results of this study demonstrate that PAC1 is a direct transcriptional target of E2F-1, and that E2F-1 suppresses ERK activity through regulation of PAC1 phosphatase. Negative regulation of MAP kinases by E2F-1 via PAC1 offers an intracellular avenue for better response of cancer cells to chemotherapeutic treatment such as 4-HPR, leading to elimination of cancer cells by apoptosis. Because E2F-1 is expressed mostly in cancer cells and PAC1 is highly responsive to oxidative stress, the identification of the E2F-1 and PAC1 pathway may provide a new direction for future developments in cancer therapy.
Materials and methods

DNA constructs
The luciferase reporter pGL3-PAC1-luc was generated by ligating the human PAC1 promoter fragments into the pGL3-basic reporter (Promega, Madison, WI, USA). A mutant form of the pGL3-PAC1, containing a point mutation in the E2F-1 consensus site, PAC1-1.2 mt-luc, was generated by using the QuikChange site-directed mutagenesis kit (Stratagene, Ceder Creek, TX, USA). pcDNA3/PAC1 expression plasmid was described previously (Yin et al., 2003) . Two human PAC1 siRNA vectors, U6/PAC1-siRNA1/2, were constructed by cloning PAC1-specific siRNA sequences into the designed sites of ApaI and EcoRI in pSilencer 1.0-U6 siRNA expression vector (Ambion, Austin, TX, USA) as previously described (Yin et al., 2003) . A 19-bp random sequence was also constructed into the pSilencer 1.0-U6 vector and the resulting U6-NS plasmid was used as a control. Also, pcDNA3/E2F-1 expression plasmid and a U6/E2F-1 siRNA plasmid were constructed.
Cell culture and gene transfection MDA-MB-435 breast cancer cell line (MB435 in the following text) and Saos-2 osteosarcoma cell line were purchased from ATCC (American Type Culture, Manassas, VA, USA). Gene transfection was conducted using Lipofectamine (Gibco/ Invitrogen Corporation, Carlsbad, CA, USA), according to the manufacturer's protocol. Stable clones were selected by hygromycin B.
Northern blotting and western blotting For northern analysis, total RNA was isolated from growing cells using trizol reagent (Gibco) and poly(A) þ RNA was purified by a PolyATtract mRNA isolation system (Promega). RNA was separated on a 1.2% formaldehyde gel and transferred to a Nybond-N membrane using a Turboblotter system (Schleicher and Schuell/Whatman Inc., Florham Park, NJ, USA). DNA probes were labeled with [a-32 P]dCTP (Amersham Biosciences, Piscataway, NJ, USA) using the prime-It RmT random primer labeling kit (Stratagene). The membrane was hybridized with labeled DNA probes in the QuickHyb hybridization (Stratagene) at 651C for 16 h. For western analysis, samples were resolved in 10% sodium dodecyl sulfate-polyacrylamide gels and then transferred onto nitrocellulose membranes. Immunoblots were incubated with primary antibodies and then with peroxidase-conjugated secondary antibodies. Antibodies used for western blotting include a PAC1 monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 4021, sc-32776) and a PAC1 polyclonal antibody (Systems Biomed, LLC., Tenafly, NJ, USA); a mouse anti-E2F-1 antibody (UBI, United Biomedical, Inc., Hauppauge, NY, USA, #05-379), a mouse anti-p-ERK antibody (Santa Cruz Biotechnology, E-4, sc-7383), an anti-ERK1 antibody (Zymed Laboratories, Inc., South San Francisco, CA, USA, #13-8600), an anti-ERK2 antibody (Zymed, #13-4800) and a goat anti-actin (Santa Cruz Biotechnology, I-19, sc-1616).
Luciferase assay
Cells were transiently cotransfected with the PAC1 luciferase reporters, pGL3-PAC1-1.2-luc,. pGL3-PAC1-1.2 mt-luc, pGL3-PAC1-0.5-luc (deletion) and the E2F-1 expression vectors, pcDNA3/E2F1 or the empty vector pcDNA3, using Lipofectamine reagent (Invitrogen Corporation, Carlsbad, CA, USA). A pCMV-b-galactosidase internal control plasmid was also introduced to each transfectant to normalize the transfection efficiency. Cell extracts in triplicate were processed using the Dual-Light kit (Tropix/Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Luciferase activity was measured with a Berthold Autolumat LB953 Rack Luminometer and luciferase values were normalized against b-galactosidase activity.
EMSA
Human GST-E2F-1 fusion protein was produced from growing Escherichia coli BL21 transfected with pGEX-2T-E2F-1. A pair of 34 bp wild-type PAC1 oligonucleotide (34W) was synthesized and labeled with [g-32 P]ATP by using T4 polynucleotide kinase. Also, for the competition and specificity controls, an excess of unlabeled wild-type PAC1 corresponding oligonucleotide (cold 34W) and a labeled random oligonucleotide (NS30W) were prepared.
32 P-labeled probes were incubated with purified recombinant GST-E2F-1 fusion protein in 20 ml DNA binding reaction buffer consisting of 20 mM Tris-HCl (pH7.5), 4% Ficoll-400, 2 mM EDTA, 0.5 mM DTT and 0.2 mg of poly(dI-dC). For supershift detection, an E2F1 monoclonal antibody (Santa Cruz, KH95X, sc-251X) was included in reactions. The reaction mixtures were incubated for 20 min, then resolved in a 4% polyacrylamide gel and exposed for autoradiography.
ChIP
Growing cells were processed for ChIP using a ChIP assay kit (UBI) according to the manufacturer's protocol. Cells were crosslinked by 1% formaldehyde and DNA was sonicated to 500-2000 bp fragments. Precleared lysates were incubated overnight with the anti-E2F-1 monoclonal antibody (UBI, #05-379) at 41C, and then the E2F-1 immune complexes were precipitated with protein A beads. After reversing DNA-protein crosslinks at 651C for 4 h, DNA was purified by phenol extraction and ethanol precipitation. The precipitated PAC1 promoter was amplified by PCR using the corresponding primers. Immunoprecipitation with another control antibody, anti-CREB (Cell Signaling Technology Inc., Danvers, MA, USA, 86B10, #9104), was included and genomic DNA from the same panel of cells was used as a positive control for the PCR reaction. The promoter of human b-actin gene was PCR-amplified used as a control. PCR products were analysed by gel electrophoresis.
Cell viability and TUNEL assay Cell viability was measured by trypan blue exclusion. The data are presented as the means7s.e. of three independent experiments of duplicate cultures. TUNEL assay for the detection of cell apoptosis was conducted by using an ApopTag Fluorescein in situ apoptosis detection kit (Upstate/ Chemicon, Temecula, CA, USA) following the manufacturer's instruction.
Statistical analysis
Statistical analysis was performed using the Statistical Analysis System for Windows (SAS). All data were analysed as a completely randomized design using standard analysis of variance procedures. All experiments were independently replicated at least three times and data were summarized as means7s.e. Two-sided P-values of Po0.05 (*) or Po0.01 (**) were considered statistically significant.
